Treatment Options for Surgically Resectable Gastric Cancer
- Lakshmi Rajdev MD, MS
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Surgery is the only curative therapy for gastric cancer. The standard recommendations for resectable gastric adenocarcinoma are free-margin surgery with at least D1 resection and the removal of a minimum of 15 lymph nodes. The overall 5-year survival rate for resected gastric patients remains poor due to locoregional recurrence. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which led to the regimen being adopted as a standard of care. More recently the MAGIC/UK Medical Research Council (MRC) trial demonstrated that perioperative chemotherapy resulted in an improvement in overall survival and progression free survival. Thus, two successful strategies are available to improve outcomes in patients with localized gastric cancer. This article reviews data on adjuvant and perioperative treatment modalities for gastric cancer. The article discusses ongoing randomized adjuvant and perioperative trials that are designed to optimize chemotherapy regimens and also investigate combinations of chemotherapy and biologic agents. It is important to understand the mechanisms or pathways involved in gastric cancer development and metastasis. Identification of novel molecules pivotal to tumor biology may lead to new therapeutic approaches for this malignancy.
- Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33. CrossRef
- Ajani JA: Chemotherapy for gastric carcinoma: new and old options. Oncology (Huntingt) 1998, 12(10 Suppl 7):44–47.
- Gunderson LL: Gastric cancer: patterns of relapse after surgical resection. Semin Radiat Oncol 2002, 12:150–161. CrossRef
- Gunderson LL, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982, 8:1–11.
- Landry J, Tepper J, Wood W, et al.: Analysis of survival and local control following surgery for gastric cancer. Int J Radiat Oncol Biol Phys 1986, 12:119.
- Landry J, Tepper J, Wood W, et al.: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990, 19:1357–1362.
- Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 1999, 230:170–178. CrossRef
- Viste A, Haugstvedt T, Eide GE, et al.: Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988, 207:7–12. CrossRef
- Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999, 79:1522–1530. CrossRef
- Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004, 22:2069–2077. CrossRef
- McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003, CD001964
- Wolff A, Davidson N: Primary systemic therapy in operable breast cancer. J Clin Oncol 2000, 18:1558–1569.
- Ajani JA, Ota DM, Jessup JM: Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501–1506. CrossRef
- Ajani JA, Mayer RJ, Ota DM: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993, 85:1839–1844. CrossRef
- Ajani JA, Mansfield PF, Lynch PM: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999, 17:2403–2411.
- Hartgrink HH, van de Velde CJH, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004, 30:643–649. CrossRef
- Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing perioperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol 2007, 25:18s (abstract 4510).
- Zhang Z-X, Gu X-Z, Yin W-B, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC): report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42:929-934.
- Fiorica F, Cartei F, Enea M, et al.: The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007, 33:729–740. CrossRef
- Ajani JA, Mansfield P, Janjan N, et al.: Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004, 22:2774–2780. CrossRef
- Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237–1244. CrossRef
- Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11–20. CrossRef
- Roth AD, et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Res (SAKK) and the European Institute of Oncology (EIO). World Congress of Gastrointestinal Cancers Barcelona, Spain, 2007
- Earle C, Maroun J: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999, 35(7):1059–1064. CrossRef
- Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000, 11(7):837–843. CrossRef
- Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810–1820. CrossRef
- Chu QS, Hammond LA, Schwartz G, et al.: Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004, 10(15):4913–4921. CrossRef
- Nakajima M, Fukami T, Yamanaka H, et al.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006, 80:282–297. CrossRef
- Fujita K, Yamamoto W, Endo H, et al.: Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1. ASCO Meeting Abstracts 2007, 25:2504.
- Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730. CrossRef
- Wagner AD, Grothe W, Haerting J, et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903–2909. CrossRef
- Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Annual Meeting of ASCO 2009; abstract #LBA4509
- Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al.: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 15:65–71.
- Treatment Options for Surgically Resectable Gastric Cancer
Current Treatment Options in Oncology
Volume 11, Issue 1-2 , pp 14-23
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Author Affiliations
- 1. Jack D. Weiler Hospital of The Albert Einstein College of Medicine, Montefiore Medical Center, 1825 Eastchester Road Rm# 2S-50, Bronx, NY, 10461, USA